Boston Scientific (BSX) Weaker After Lotus Valve Device Recall
- Wall Street ends mixed after punishing week
- Broadcom (AVGO) in Talks to Acquire VMware (VMW) - WSJ
- '3600 is the New Bull Case': Outflows from Energy and Materials Highest in Several Years - BofA
- Dollar catches a break after bruising week as investors turn risk averse
- Apple (AAPL) is a 'Compelling Name To Own' Right Now, iPhone Sales Trending Ahead of Guidance - Wedbush's Ives
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Boston Scientific (NYSE: BSX) is down 6.9% after the company announced a voluntary removal of all Lotus Valve devices, including Lotus with Depth Guard™, from global commercial and clinical sites due to reports of premature release of a pin connecting the Lotus Valve to the delivery system. As with the prior announced suspension of the Lotus Edge Valve System device, they believe that the issue is caused by excess tension in the pin mechanism introduced during the manufacturing process.
The company expects to bring the Lotus Valve platform back to market in Europe and other regions in the fourth quarter of 2017. They anticipate filing the U.S. PMA submission for the Lotus Edge Valve System, the next generation platform, in the fourth quarter of 2017, with a U.S. launch planned for mid-2018.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OraSure Technologies (OSUR) on Watch as DOH to Buy Ebola Test
- Altamira Therapeutics (CYTO) Reports Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
- Foghorn Therapeutics (FHTX) Phase 1 Study of FHD-286 Placed on Partial Clinical Hold
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!